Idera Pharmaceuticals
As of the edition of 20 October 2026, Idera Pharmaceuticals runs 2 drugs; it is on route A at 3 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Aceragen: acquired in 2022; successor Idera Pharmaceuticals, Inc.
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
Where it needs a new molecule
Route A at 3 targets, route B at 0 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Idera Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 5 trials led
- Skin and connective tissue: 4 trials led
- Blood and lymph: 2 trials led